Looking ahead, he is determined to expand access to life-saving gene therapy medication for patients suffering from rare diseases.
LAKE VILLA, IL, October 01, 2024 /24-7PressRelease/ — Carl Denny has been included in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Mr. Denny’s professional journey is a testament to his dedication and expertise in regulatory affairs, clinical development, and biotechnology. He currently serves as the Senior Vice President and Head of Regulatory Affairs for Abeona Therapeutics Inc., a role he assumed in 2021. His career path includes significant roles at Sarepta Therapeutics, Inc., AveXis, Inc., GE Healthcare, Catalent, Abbott, Takeda Pharmaceutical Company Limited, and Eli Lilly and Company. His international experience as a regulatory consultant for Gilead Sciences, and his extensive work with 11 regulatory agencies, have honed his skills in biologic and gene therapy drug registrations across the globe.
Mr. Denny’s academic journey was a foundation for his professional success. He holds a Bachelor of Science in Chemistry from Illinois State University, a Master of Science in Chemistry from Purdue University and is Regulatory Affairs Certified from the Regulatory Affairs Professional Society (RAPS) in US FDA regulations. His commitment to staying updated with industry changes is evident in his association with the Regulatory Affairs Professional Society. Beyond his professional work, Mr. Denny also contributes to his community through his family support of Matthias Academy, a nonprofit adult day program in southeast Wisconsin that serves adults with mild to severe disabilities.
Mr. Denny’s professional journey is studded with achievements. His dedication to excellence has been recognized with several achievement awards from Abbott and Eli Lilly. His career is filled with highlights, but he takes the most pride in obtaining approvals for two gene therapies: an AAV-based therapy, and an mRNA modifier. Mr. Denny is currently working to bring an autologous cell therapy product to the market. His work at AveXis, particularly the approval of Zolgensma, the first gene therapy with which he was involved, is a significant milestone. A single infusion of this medicine administered soon after birth has saved the lives of many babies suffering from spinal muscular atrophy.
Mr. Denny’s hard work and dedication have brought him far in his career. He credits his success to his drive and conviction, which led him to a vital conversation with his stepfather, who encouraged him to pursue higher education. Additionally, the owners and colleagues at his first factory job encouraged him to pursue his dreams and provided valuable career perspective. Without his parents’ support and his best friend’s father’s mentorship, he would not be where he is today. Looking ahead, he is determined to expand access to life-saving gene therapy medication for patients suffering from rare diseases. Currently, about 4,000 patients in the United States could benefit from this medication, and he is committed to increasing this number in the coming years.
About Marquis Who’s Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who’s Who in America®, Marquis Who’s Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who’s Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who’s Who® website, www.marquiswhoswho.com.
# # #
